Literature DB >> 6109012

Amphetamine-haloperidol interactions on striatal and mesolimbic tyrosine hydroxylase activity and dopamine metabolism.

R Kuczenski.   

Abstract

Rat striatal and mesolimbic dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid levels and the activity of tyrosine hydroxylase (TOH) were determined as a function of dose of amphetamine (AMPH) or haloperidol (HAL). AMPH increases DA levels with an ED50 of 0.6 mg/kg and decreases DOPAC and homovanillic acid levels with an ED50 of 1.5 mg/kg, suggesting two sites of action for the drug. HAL increases DOPAC and homovanillic acid levels and activates TOH all with an ED50 near 0.05 mg/kg and maximal activation at 0.2 mg/kg. AMPH administered subsequent to 0.2 mg/kg of HAL has no effect on mesolimbic TOH activity or DA metabolism. In contrast AMPH after HAL still increases striatal DA levels and, in addition, partially reverses the HAL-induced increases in both DOPAC levels and TOH activity, all with an ED50 near 0.6 mg/kg. The maximal reversal by AMPH is near 25% of the HAL-induced increases with doses of AMPH to 10 mg/kg. The ED50 for AMPH reversal and the extent of reversal are independent of HAL dose. The equivalent reversal by AMPH of HAL-induced increases in striatal TOH activity and DOPAC levels suggest a neuronally mediated phenomenon involving a noncompetitive interaction between the two drugs on the nigrostriatal pathway. The data are discussed in terms of sites of action for AMPH in both the striatum and the substantia nigra.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6109012

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  "Designer" amphetamines: effects on behavior and monoamines with or without reserpine and/or alpha-methyl-para-tyrosine pretreatment.

Authors:  M T Martin-Iverson; N Yamada; A W By; B A Lodge
Journal:  J Psychiatry Neurosci       Date:  1991-12       Impact factor: 6.186

2.  Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission.

Authors:  P Bredeloux; I Dubuc; J Costentin
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

3.  Influence of chronic inorganic lead exposure on regional dopamine and 5-hydroxytryptamine turnover in rat brain.

Authors:  S M Lasley; R D Greenland; D J Minnema; I A Michaelson
Journal:  Neurochem Res       Date:  1984-12       Impact factor: 3.996

4.  Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

Authors:  S Hjorth; A Carlsson; D Clark; K Svensson; H Wikström; D Sanchez; P Lindberg; U Hacksell; L E Arvidsson; A Johansson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Altered central monoamine response to D-amphetamine in rats chronically exposed to inorganic lead.

Authors:  S M Lasley; R D Greenland; D J Minnema; I A Michaelson
Journal:  Neurochem Res       Date:  1985-07       Impact factor: 3.996

6.  (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists.

Authors:  K Svensson; A M Johansson; T Magnusson; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

7.  The effects of (+)-amphetamine, alpha-methyltyrosine, and alpha-methylphenylalanine on the concentrations of m-tyramine and alpha-methyl-m-tyramine in rat striatum.

Authors:  D F Dougan; A M Duffield; P H Duffield; D N Wade
Journal:  Br J Pharmacol       Date:  1983-10       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.